Andreana N. Holowatyj, PhD, MS, Discusses Focal Questions Regarding Colorectal Cancer Disparities

Video

Holowatyj touched on the need to learn more about the biological factors contributing to disparities in early-onset colorectal cancer and the associated burden of the disease.

Andreana N. Holowatyj, PhD, MS, of the Vanderbilt University Medical Center, spoke with CancerNetwork about the focal questions from her research presented at the American Association for Cancer Research (AACR) Annual Meeting 2021 focusing on disparities in early-onset colorectal cancer.

Transcription:

We sought to tackle the loaded question to understand what biological factors may be contributing to disparities in the early-onset colorectal cancer burden. To put things into perspective, overall about 1 in every 10 colorectal cancer cases is diagnosed prior to age 50. There’s been a challenge to date in accruing sufficient cases or data to be able to explore this timely and important research question as to differences within the population of early-onset colorectal cancer, particularly the molecular features. It was a really unique opportunity to leverage the resource of the AACR Project GENIE [Genomic Evidence Neoplasia Information Exchange] consortium that included both clinical-grade targeted sequencing data, and clinical demographic data on cases with a pathologically confirmed colorectal cancer diagnosis from 12 institutions worldwide, which was [a] prime opportunity to answer this research question with over 6000 colorectal cancer cases included in our study.

Reference:

Holowatyj AN, Wen W, Gibbs T, et al. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases. Presented at: AACR Annual Meeting 2021. Virtual. Abstract 101.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Related Content